-
1.发明申请NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER 失效核酸和相关蛋白125P5C8有效治疗和检测癌症公开(公告)号：US20100266498A1
公开(公告)日：2010-10-21
申请号：US12820083
申请日：2010-06-21
申请人： Mary FARIS , Pia M. Challita-Eid , Rene S. Hubert , Daniel E. H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
发明人： Mary FARIS , Pia M. Challita-Eid , Rene S. Hubert , Daniel E. H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
IPC分类号： A61K51/10 , C07K14/435 , A61K39/395 , A61P35/00 , G01N33/53 , C12Q1/68 , C12N5/09
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , Y02A50/466
摘要： A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
摘要翻译： 描述了一种新型基因（称为125P5C8）及其编码的蛋白及其变体，其中125P5C8在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，125P5C8提供诊断，预后， 癌症的预防和/或治疗靶标。 125P5C8基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与125P5C8反应的抗体或T细胞可用于主动或被动免疫。
-
2.发明申请NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER 失效核酸和对照蛋白质202P5A5有用于治疗和检测癌症公开(公告)号：US20110201052A1
公开(公告)日：2011-08-18
申请号：US13021202
申请日：2011-02-04
CPC分类号： C12N5/0693 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K47/6851 , A61K2039/505 , C07K14/435 , C07K14/47 , C07K2319/00 , G01N33/57484 , Y02A50/466
摘要： A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 202P5A5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 202P5A5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 can be used in active or passive immunization.
摘要翻译： 描述了一种新型基因202P5A5及其编码的蛋白质及其变体，其中202P5A5在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，202P5A5提供诊断，预后，预防和/ 或癌症的治疗靶标。 202P5A5基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与202P5A5反应的抗体或T细胞可用于主动或被动免疫。
-
3.发明申请NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 162P1E6 USEFUL IN TREATMENT AND DETECTION OF CANCER 失效核酸和相关蛋白162P1E6用于治疗和检测癌症公开(公告)号：US20110171127A1
公开(公告)日：2011-07-14
申请号：US13052002
申请日：2011-03-18
申请人： Mary FARIS , Pia M. Challita-Eid , Rene S. Hubert , Daniel H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
发明人： Mary FARIS , Pia M. Challita-Eid , Rene S. Hubert , Daniel H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
IPC分类号： A61K51/10 , G01N33/566 , C12N5/09 , C12Q1/68 , A61K39/395 , A61P35/00
CPC分类号： C07K14/4748 , A61K31/7088 , A61K38/1764 , C12Q1/6886 , C12Q2600/158 , G01N33/574 , G01N33/57434
摘要： A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
摘要翻译： 描述了一种新型基因（称为125P5C8）及其编码的蛋白及其变体，其中125P5C8在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，125P5C8提供诊断，预后， 癌症的预防和/或治疗靶标。 125P5C8基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与125P5C8反应的抗体或T细胞可用于主动或被动免疫。
-
4.发明申请NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 282P1G3 USEFUL IN TREATMENT AND DETECTION OF CANCER 审中-公开核酸和相关蛋白质完成282P1G3有用的治疗和检测癌症公开(公告)号：US20090252747A1
公开(公告)日：2009-10-08
申请号：US12400679
申请日：2009-03-09
IPC分类号： A61K39/395 , C07K16/00 , A01K67/027 , C12N5/12 , C12N15/63 , A61P35/00
CPC分类号： C12N5/0693 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K47/6851 , A61K2039/505 , C07K14/435 , C07K14/47 , C07K2319/00 , G01N33/57484 , Y02A50/466
摘要： A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.
摘要翻译： 描述了一种新型基因282P1G3及其编码的蛋白及其变体，其中282P1G3在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，282P1G3提供诊断，预后，预防和/ 或癌症的治疗靶标。 282P1G3基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与282P1G3反应的抗体或T细胞可用于主动或被动免疫。
-
-
-
搜索结果
4 条记录 (耗时 0.051 秒)
